RxDoctor Payments Data

Andrew Sun, MD

Gastroenterology · Cincinnati, OHNPI 1184653669

Payments from drug & device makers

$14,926in general payments, 2019–2025

Across 879 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Regeneron Healthcare Solutions, Inc.$670
  • Abbott$615
  • plus $6K from 38 others

What the payments were for

  • Food & beverage$14,40897%
  • Education$5183%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,926 in reported general payments places this provider in the 75th percentile of 657 gastroenterology providers in Ohio.

See all gastroenterology providers in Ohio

Medicare billing

Part B allowed, 2024
$157,232
Medicare patients
348
Services billed
5,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab21$148,917
LinzessLinaclotide98$90,465
ZenpepLipase/Protease/Amylase21$65,864
ViberziEluxadoline21$35,682
XifaxanRifaximin11$33,635
Mesalamine36$15,436
Budesonide DrBudesonide55$9,836
TrulancePlecanatide14$8,994
Dexlansoprazole DrDexlansoprazole30$8,017
Colestipol Hcl73$7,611
Budesonide EcBudesonide21$7,334
Mesalamine ErMesalamine30$6,717
Ursodiol29$6,296
Tenofovir Disoproxil Fumarate24$5,411
MovantikNaloxegol Oxalate13$5,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Viberzi$3,667$126,147119 claims
Aimmune Therapeutics, Inc.Zenpep$113$65,86421 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$1,152$42,62925 claims
Redhill Biopharma Inc.Movantik$235$5,27413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 657 gastroenterology providers in Ohio.

Other gastroenterology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →